GlassScriptPhysician profile
Aneta Maczuga
NPI 1053019729
$2,081.10
in general payments reported to CMS, 2019-2025
25 companies · $1,453 in 2025
The $1,453 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $261 · 2024: $367 · 2025: $1,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,081.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $463.72 | 2023-2025 | Aquabeam Robotic System, Aquabeam System |
| Janssen Biotech, INC. | $253.39 | 2025 | Erleada |
| Abbvie INC. | $210.95 | 2024-2025 | |
| Coloplast Corp | $164.31 | 2025 | |
| Olympus America INC. | $150.01 | 2024-2025 | Itind System |
| Bayer Healthcare Pharmaceuticals INC. | $101.95 | 2023-2025 | |
| Blue Earth Diagnostics | $99.21 | 2025 | Posluma |
| Merck Sharp & Dohme LLC | $88.49 | 2023-2025 | Keytruda, Lynparza |
| Urogen Pharma, INC. | $63.55 | 2025 | |
| Immunitybio, INC. | $60.44 | 2025 | |
| Novartis Pharmaceuticals Corporation | $59.77 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $44.50 | 2024 | Gemtesa |
| Tolmar, INC. | $40.00 | 2025 | Eligard, Jatenzo |
| Avation Medical, INC. | $37.51 | 2025 | Vivally System |
| Smith+Nephew, INC. | $33.23 | 2024 | Stravix Pl, Grafix |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $29.91 | 2024 | Lynparza |
| Teleflex LLC | $24.53 | 2025 | Urolift |
| Calyxo, INC. | $24.20 | 2025 | Cvac Aspiration System |
| 180 Medical, INC. | $23.37 | 2023 | Cure Catheter |
| Endo USA, INC. | $22.99 | 2024 | Xiaflex |
| Sagent Pharmaceuticals | $19.23 | 2025 | Glydo |
| Astellas Pharma US INC | $18.68 | 2025 | Xtandi |
| Antares Pharma, INC. | $18.34 | 2025 | Xyosted |
| Mission Pharmacal Company | $15.18 | 2023 | Uribel |
| Myriad Genetic Laboratories, INC. | $13.64 | 2024 | Prolaris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aneta Maczuga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.